Inclisiran (ALN-PCSsc), a double-stranded small interfering RNA (siRNA) compound, serves as the antisense of itself and targets PCSK-9 transcription inhibition. It is employed in the study of hyperlipidemia and cardiovascular disease (CVD) [1].